Aromatase over expression transgenic murine models for aromatase inhibitor studies

Molecular Human Reproduction

Volumn 16, Issue 2, 2009, Pages 80-86

  Li, Xiangdong ^a  

^a CHINA AGRICULTURAL UNIVERSITY   (China)

Author keywords

Androgen; Aromatase inhibitors; Aromatase overexpression; Estrogen excess; Estrogen ratio; Transgenic mice

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; ANTIESTROGEN; AROMATASE; AROMATASE INHIBITOR; CLOMIFENE CITRATE; ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR; ESTROGEN SULFOTRANSFERASE; FINROZOLE; FOLLITROPIN; GONADOTROPIN; LACTOFERRIN; LETROZOLE; LUTEINIZING HORMONE; PLACEBO; PROGESTERONE RECEPTOR; TESTOSTERONE; UBIQUITIN C;

BREAST CANCER; BREAST HYPERPLASIA; CANCER PREVENTION; CARCINOGENESIS; CRYPTORCHISM; DRUG MEGADOSE; ENDOMETRIOSIS; ENDOMETRIUM CARCINOMA; ESTROGEN SYNTHESIS; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; GENETIC SUSCEPTIBILITY; GYNECOMASTIA; HUMAN; INGUINAL HERNIA; LEYDIG CELL TUMOR; LIVER CELL CARCINOMA; LOW DRUG DOSE; MALE INFERTILITY; MOUSE MAMMARY TUMOR ONCOVIRUS; NONHUMAN; OVULATION INDUCTION; POSTMENOPAUSE; PRIORITY JOURNAL; REVIEW; SPERMATOGENESIS; TESTIS TUMOR; TRANSGENIC MOUSE; TUMOR GROWTH; UTERINE CERVIX CARCINOMA; ANIMAL; ARTICLE; DRUG EFFECT; ENZYME ACTIVATION; FEMALE; GENETICS; MALE; METABOLISM; MOUSE;

MURINAE; MUS MUSCULUS;

ANDROGENS; ANIMALS; AROMATASE; AROMATASE INHIBITORS; ENZYME ACTIVATION; ESTROGENS; FEMALE; HUMANS; MALE; MICE; MICE, TRANSGENIC;

EID: 77949532215     PISSN: 13609947     EISSN: 14602407     Source Type: Journal    
DOI: 10.1093/molehr/gap070     Document Type: Review

References (71)

1. Adami HO, Bergstrom R, Mohner M, Zatonski W, Storm H, Ekbom A, Tretli S, Teppo L, Ziegler H, Rahu M et al. Testicular cancer in nine northern European countries. Int J Cancer 1994;59:33-38.
2. Ahmed S. A novel molecular modelling study of inhibitors of the 17alpha-hydroxylase component of the enzyme system 17alpha-hydroxylase/17,20-lyase (P-450(17alpha)). Bioorg Med Chem 1999;7:1487-1496.
3. Bouillon R. Estrogens are essential for male pubertal periosteal bone expansion. J. Clin. Endocrinol. Metab. 2004;89:6025-6029.
4. Brodie A, Lu Q, Liu Y, Long B. Aromatase inhibitors and their antitumor effects in model systems. Endocr Relat Cancer 1999;6:205-210.
5. Bulun SE, Noble LS, Takayama K, Michael MD, Agarwal V, Fisher C, Zhao Y, Hinshelwood MM, Ito Y, Simpson ER. Endocrine disorders associated with inappropriately high aromatase expression. J Steroid Biochem Mol Biol 1997;61:133-139.
6. Bulun SE, Mao CS, Brasel JA, Neely EK. Treatment of gynecomastia and hypogonadism in disorders of excessive estrogen formation using an aromatase inhibitor. Endocr Soc 1999a;OR:79-87.
7. Bulun SE, Zeitoun K, Takayama K, Noble L, Michael D, Simpson E, Johns A, Putman M, Sasano H. Estrogen production in endometriosis and use of aromatase inhibitors to treat endometriosis. Endocr Relat Cancer 1999b;6:293-301.
8. Carani C, Qin K, Simoni M, Faustini-Fustini M, Serpente S, Boyd J, Korach KS, Simpson ER. Effect of testosterone and estradiol in a man with aromatase deficiency. N Engl J Med 1997;337:91-95.
9. Coleman K, Smith C. Ubtracellular signaling pathwyas: nongenomic actions of estrogens and liagnd-independent activationof estrogen receptors. Front. Biosci. 2001;6:D1379-D1391.
10. De Coster R, Wouters W, Bruynseels J. P450-dependent enzymes as targets for prostate cancer therapy. J Steroid Biochem Mol Biol 1996;56:133-143.
11. Deladoey J, Fluck C, Bex M, Yoshimura N, Harada N, Mullis PE. Aromatase deficiency caused by a novel P450arom gene mutation: impact of absent estrogen production on serum gonadotropin concentration in a boy. J Clin Endocrinol Metab 1999;84:4050-4054.
12. Evans CT, Corbin CJ, Saunders CT, Merrill JC, Simpson ER, Mendelson CR. Regulation of estrogen biosynthesis in human adipose stromal cells. Effects of dibutyryl cyclic AMP, epidermal growth factor, and phorbol esters on the synthesis of aromatase cytochrome P-450. J Biol Chem 1987;262:6914-6920.
13. Feuillan PP, Foster CM, Pescovitz OH, Hench KD, Shawker T, Dwyer A, Malley JD, Barnes K, Loriaux DL, Cutler GB Jr. Treatment of precocious puberty in the McCune-Albright syndrome with the aromatase inhibitor testolactone. N Engl J Med 1986;315:1115-1119.
14. Feuillan PP, Jones J, Cutler GB Jr. Long-term testolactone therapy for precocious puberty in girls with the McCune-Albright syndrome. J Clin Endocrinol Metab 1993;77:647-651.
15. Feuillan P, Merke D, Leschek EW, Cutler GB Jr. Use of aromatase inhibitors in precocious puberty. Endocr Relat Cancer 1999;6:303-306.
16. Feuillan P, Calis K, Hill S, Shawker T, Robey PG, Collins MT. Letrozole treatment of precocious puberty in girls with the McCune-Albright syndrome: a pilot study. J Clin Endocrinol Metab 2007;92:2100-2106.
17. Fisher CR, Graves KH, Parlow AF, Simpson ER. Characterization of mice deficient in aromatase (ArKO) because of targeted disruption of the cyp19 gene. Proc Natl Acad Sci USA 1998;95:6965-6970.
18. Fowler KA, Gill K, Kirma N, Dillehay DL, Tekmal RR. Overexpression of aromatase leads to development of testicular leydig cell tumors: an in vivo model for hormone-mediated TesticularCancer. Am J Pathol 2000;156:347-353.
19. Gill K, Kirma N, Tekmal RR. Overexpression of aromatase in transgenic male mice results in the induction of gynecomastia and other biochemical changes in mammary glands. J Steroid Biochem Mol Biol 2001;77:13-18.
20. Hall JM, Couse JF, Korach KS. The multifaceted mechanisms of estradiol and estrogen receptor signaling. J Biol Chem 2001;276:36869-36872.
21. Herrmann BL. Impact of estrogen replacement therapy in a male with congenital aromatase deficiency caused by a novel mutation in the CYP19 gene. J. Clin. Endocrinol. Metab. 2002;87:5476-5484.
22. Holzer H, Casper R, Tulandi T. A new era in ovulation induction. Fertil Steril 2006;85:277-284.
23. Honda S, Harada N, Ito S, Takagi Y, Maeda S. Disruption of sexual behavior in male aromatase-deficient mice lacking exons 1 and 2 of the cyp19 gene. Biochem Biophys Res Commun 1998;252:445-449.
24. Kafy S, Tulandi T. New advances in ovulation induction. Curr Opin Obstet Gynecol 2007;19:248-252.
25. Keshava N, Mandava U, Kirma N, Tekmal R. Acceleration of mammary neoplasia in aromatase transgenic mice by 7,12-dimethylbenz[a]anthracene. Cancer Lett. 2001;167:125-133.
26. Killackey MA, Hakes TB, Pierce VK. Endometrial adenocarcinoma in breast cancer patients receiving antiestrogens. Cancer Treat Rep 1985;69:237-238
27. Kirma N, Gill K, Mandava U, Tekmal RR. Overexpression of aromatase leads to hyperplasia and changes in the expression of genes involved in apoptosis, cell cycle, growth, and tumor suppressor functions in the mammary glands of transgenic mice. Cancer Res 2001;61:1910-1918.
28. Krege JH, Hodgin JB, Couse JF, Enmark E, Warner M, Mahler JF, Sar M, Korach KS, Gustafsson JA, Smithies O. Generation and reproductive phenotypes of mice lacking estrogen receptor beta. Proc Natl Acad Sci USA 1998;95:15677-15682.
29. Li X, Rahman N. Impact of androgen/estrogen ratio: lessons learned from the aromatase over-expression mice. Gen Comp Endocrinol 2008;159:1-9.
30. Li X, Nokkala E, Yan W, Streng T, Saarinen N, Warri A, Huhtaniemi I, Santti R, Makela S, Poutanen M. Altered structure and function of reproductive organs in transgenic male mice overexpressing human aromatase. Endocrinology 2001;142:2435-2442.
31. Li X, Warri A, Makela S, Ahonen T, Streng T, Santti R, Poutanen M. Mammary gland development in transgenic male mice expressing human P450 aromatase. Endocrinology 2002;143:4074-4083.
32. Li X, Makela S, Streng T, Santti R, Poutanen M. Phenotype characteristics of transgenic male mice expressing human aromatase under ubiquitin C promoter. J Steroid Biochem Mol Biol 2003;86:469-476.
33. Li X, Strauss L, Makela S, Streng T, Huhtaniemi I, Santti R, Poutanen M. Multiple structural and functional abnormalities in the p450 aromatase expressing transgenic male mice are ameliorated by a p450 aromatase inhibitor. Am J Pathol 2004;164:1039-1048.
34. Li X, Strauss L, Kaatrasalo A, Mayerhofer A, Huhtaniemi I, Santti R, Makela S, Poutanen M. Transgenic mice expressing p450 aromatase as a model for male infertility associated with chronic inflammation in the testis. Endocrinology 2006;147:1271-1277.
35. Lubahn DB, Moyer JS, Golding TS, Couse JF, Korach KS, Smithies O. Alteration of reproductive function but not prenatal sexual development after insertional disruption of the mouse estrogen receptor gene. Proc Natl Acad Sci USA 1993;90:11162-11166.
36. Luthra R, Kirma N, Jones J, Tekmal R. Use of letrozole as a chemopreventive agent in aromatase overexpressing transgenic mice. J Steroid Biochem Mol Biol. 2003;86:461-467.
37. Maffei L. Dysmetabolic syndrome in a man with a novel mutation of the aromatase gene: effects of testosterone, alendronate, and estradiol treatment. J. Clin. Endocrinol. Metab. 2004;89:61-70.
38. Mahendroo MS. Tissue-specific and hormonally controlled alternative promoters regulate aromatase cytochrome P450 gene expression in human adipose tissue. J. Biol. Chem 1993;268:19463-19470.
39. Mandava U, Kirma N, Tekmal R. Aromatase overexpression transgenic mice model: cell type specific expression and use of letrozole to abrogate mammary hyperplasia without affecting normal physiology. J Steroid Biochem Mol Biol. 2001;79:27-34.
40. McLachlan JA, Newbold RR, Bullock B. Reproductive tract lesions in male mice exposed prenatally to diethylstilbestrol. Science 1975;190:991-992
41. McLachlan JA, Newbold RR, Bullock BC. Long-term effects on the female mouse genital tract associated with prenatal exposure to diethylstilbestrol. Cancer Res 1980;40:3988-3999.
42. Miller WR. Aromatase activity in breast tissue. J Steroid Biochem Mol Biol 1991;39:783-790.
43. Miller WR. Aromatase inhibitors-where are we now? Br J Cancer 1996;73:415-417.
44. Miller WR, O'Neill J. The importance of local synthesis of estrogen within the breast. Steroids 1987;50:537-548.
45. Mitwally MF, Casper RF. Use of an aromatase inhibitor for induction of ovulation in patients with an inadequate response to clomiphene citrate. Fertil Steril 2001;75:305-309.
46. Mitwally MF, Casper RF. Aromatase inhibition improves ovarian response to follicle-stimulating hormone in poor responders. Fertil Steril 2002;77:776-780.
47. Mitwally MF, Casper RF. Aromatase inhibition reduces gonadotrophin dose required for controlled ovarian stimulation in women with unexplained infertility. Hum Reprod 2003;18:1588-1597.
48. Mitwally MF, Casper RF. Single-dose administration of an aromatase inhibitor for ovarian stimulation. Fertil Steril 2005;83:229-231.
49. Mitwally MF, Biljan MM, Casper RF. Pregnancy outcome after the use of an aromatase inhibitor for ovarian stimulation. Am J Obstet Gynecol 2005;192:381-386.
50. Moller H. Trends in incidence of testicular cancer and prostate cancer in Denmark. Hum Reprod 2001;16:1007-1011.
51. Morishima A, Grumbach MM, Simpson ER, Fisher C, Qin K. Aromatase deficiency in male and female siblings caused by a novel mutation and the physiological role of estrogens. J Clin Endocrinol Metab 1995;80:3689-3698.
52. Nair H, Luthra R, Kirma N, Liu Y, Flowers L, Evans D, Tekmal R. Induction of aromatase expression in cervical carcinomas: effects of endogenous estrogen on cervical cancer cell proliferation. Cancer Res 2005;65:11164-11173.
53. Peng Z, Li X, Makela S, Vaananen HK, Poutanen M. Skeletal changes in transgenic male mice expressing human cytochrome p450 aromatase. J Bone Miner Res 2004;19:1320-1328.
54. Qian YM, Sun XJ, Tong MH, Li XP, Richa J, Song WC. Targeted disruption of the mouse estrogen sulfotransferase gene reveals a role of estrogen metabolism in intracrine and paracrine estrogen regulation. Endocrinology 2001;142:5342-5350.
55. Robertson KM, Simpson ER, Lacham-Kaplan O, Jones ME. Characterization of the fertility of male aromatase knockout mice. J Androl 2001;22:825-830.
56. Seralini G, Moslemi S. Aromatase inhibitors: past, present and future. Mol Cell Endocrinol 2001;178:117-131.
57. Sharpe R. Do males rely on female hormones? Nature 1997;390:447-448.
58. Sharpless NE, Depinho RA. The mighty mouse: genetically engineered mouse models in cancer drug development. Nat Rev Drug Discov 2006;5:741-754.
59. Simpson ER, Mahendroo MS, Means GD, Kilgore MW, Hinshelwood MM, Graham-Lorence S, Amarneh B, Ito Y, Fisher CR, Michael MD et al. Aromatase cytochrome P450, the enzyme responsible for estrogen biosynthesis. Endocr Rev 1994;15:342-355.
60. Simpson ER, Michael MD, Agarwal VR, Hinshelwood MM, Bulun SE, Zhao Y. Cytochromes P450 11: expression of the CYP19 (aromatase) gene: an unusual case of alternative promoter usage. Faseb J 1997;11:29-36.
61. Simpson ER, Clyne C, Speed C, Rubin G, Bulun S. Tissue-specific estrogen biosynthesis and metabolism. Ann N Y Acad Sci 2001;949:58-67.
62. Smith C, O'Malley B. Coregulator function: a key to understanding tissue specificity of selective receptor modulators. Endocr. Rev. 2004;20:321-344.
63. Streng T, Li X, Lehtoranta M, Makela S, Poutanen M, Talo A, Tekmal RR, Santti R. Infravesical obstruction in aromatase over expressing transgenic male mice with increased ratio of serum estrogen-to-androgen concentration. J Urol 2002;168:298-302.
64. Suggitt M, Bibby MC. 50 years of preclinical anticancer drug screening: empirical to target-driven approaches. Clin Cancer Res 2005;11:971-981.
65. Tekmal RR, Ramachandra N, Gubba S, Durgam VR, Mantione J, Toda K, Shizuta Y, Dillehay DL. Overexpression of int-5/aromatase in mammary glands of transgenic mice results in the induction of hyperplasia and nuclear abnormalities. Cancer Res 1996;56:3180-3185.
66. Tekmal R, Kirma N, Gill K, Fowler K. Aromatase overexpression and breast hyperplasia, an in vivo model-continued overexpression of aromatase is sufficient to maintain hyperplasia without circulating estrogens, and aromatase inhibitors abrogate these preneoplastic changes in mammary glands. Endocr Relat Cancer 1999;6:307-314.
67. Toda K, Takeda K, Okada T, Akira S, Saibara T, Kaname T, Yamamura K, Onishi S, Shizuta Y. Targeted disruption of the aromatase P450 gene (Cyp19) in mice and their ovarian and uterine responses to 17beta-oestradiol. J Endocrinol 2001;170:99-111.
68. Vanderhyden BC, Shaw TJ, Ethier JF. Animal models of ovarian cancer. Reprod Biol Endocrinol 2003;1:67.
69. Villa E, Camellini L, Dugani A, Zucchi F, Grottola A, Merighi A, Buttafoco P, Losi L, Manenti F. Variant estrogen receptor messenger RNA species detected in human primary hepatocellular carcinoma. Cancer Res 1995;55:498-500.
70. Villa E, Dugani A, Fantoni E, Camellini L, Buttafoco P, Grottola A, Pompei G, De Santis M, Ferrari A, Manenti F. Type of estrogen receptor determines response to antiestrogen therapy. Cancer Res 1996;56:3883-3885.
71. Villa E, Colantoni A, Camma C, Grottola A, Buttafoco P, Gelmini R, Ferretti I, Manenti F. Estrogen receptor classification for hepatocellular carcinoma: comparison with clinical staging systems. J Clin Oncol 2003; 21:441-446.